TAMPA, Fla. (August. 23, 2017) – M2Gen®, announced today that it has expanded its leadership by appointing M2Gen Founder William S. Dalton, PhD, MD as the new Founder & Executive Chair and naming Timothy R. Wright as its new President and Chief Executive Officer. M2Gen, a for-profit subsidiary of Moffitt Cancer Center, is a health informatics solutions company focused on advancing personalized medicine by combining high quality molecular data and clinical data in an informatics environment to accelerate discovery and delivery of personalized medicine.
William S. Dalton, PhD, MD, who founded M2Gen and has been its CEO since 2012, will lead the M2Gen Board of Directors and focus on promoting the science and vision of M2Gen and growth of the Oncology Research Information Exchange Network® (ORIEN), an alliance of 16 cancer centers from across the United States with more than 185,000 patients participating in ORIEN’s lifetime study, Total Cancer Care®.
M2Gen’s newly appointed CEO, Tim Wright, will assume financial and operational leadership of M2Gen, helping the organization expand its business portfolio. Wright has more than 30 years of experience in the pharma and biotech industries. Most recently he served as the Executive Vice President of Business Development, Strategy and Commercial Innovation at TEVA Pharmaceutical Industries, Ltd. He is the founder and Chairman of the Drug Discovery and Development Institute for the Ohio State University Comprehensive Cancer Center and served as a Director for several years. Wright is a member of The Ohio State University Innovation Foundation, the technology transfer arm of OSU’s Comprehensive Cancer Center. Additionally, he has held the roles CEO and president at several pharma companies, including Covidien and Elan.
“M2Gen has seen considerable growth in the last year. It now manages ORIEN, the world’s largest cancer-focused data warehouse linking clinical and molecular data, and the ORIEN Avatar® Research Program, a partnership with pharmaceutical companies aimed at accelerating the discovery and development of novel cancer therapies,” said Dalton, founder of M2Gen and ORIEN. “This leadership change will allow M2Gen to focus on expanding ORIEN while also enhancing its brand and services in the personalized medicine field.”